Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gene Therapy Approvals By US FDA Could Double In 2020

Jan 26 2020

• By Bridget Silverman

Related Content

J.P. Morgan Notebook Day 1: No Big Deals, But Plenty Of Pipeline, Commercial Highlights

Jan 14 2020

J.P. Morgan Notebook Day 4: Novartis CEO Weighs In On AI, Sangamo’s Next Steps And More

Jan 17 2020

Fresh Or Frozen? Orchard Aims For Cryopreserved Gene Therapy Approvals Using Pivotal Trials With Fresh Cell Formulations

Aug 05 2019

Keeping Track: Oxbryta Approval Headlines Pre-Thanksgiving Week Of News

Dec 01 2019

Keeping Track, Oncology Edition: Biologic Breakthroughs And BLAs

Dec 11 2019

Gene Therapy Manufacturing Hitch Solved, Bluebird Aims For European Debut In 2020

Oct 24 2019

Bristol’s CAR-T Strategy Comes Into Focus With Two Near-Term Filings

Dec 10 2019

Kite Readies A Second CAR-T For Filing As CD19 Competition Grows

Dec 11 2019

Related Companies

Spark Therapeutics, Inc.

Novartis AG

Kite Pharma, Inc.

Gilead Sciences, Inc.

Bristol Myers Squibb Company

Bristol Myers Squibb Company

BioMarin Pharmaceutical Inc.

Bristol Myers Squibb Company

Sangamo Therapeutics, Inc.

Pfizer Inc.

Ferring Pharmaceuticals

Amgen, Inc.

Genetix Biotherapeutics

Johnson & Johnson

Genscript Biotech Corporation

Orchard Therapeutics Limited

Mesoblast Limited

Additional Topics

United States Gene Therapy Drug Review Approvals Regenerative Medicine Regulation Drug Approval Standards BioPharmaceutical Pink Sheet Perspectives

More from Cell & Gene Therapies

More from Advanced Technologies

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window